Ra223 in Bone Metastases with Osteolytic Activity

Radium 223 dichloride (Ra223) is the only targeted alpha therapy able to extend survival in patients with bone metastases from prostate cancer. Mechanism of action and data currently available focused mainly on osteoblastic metastases from prostate cancer. In our institution, a patient with breast c...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Renato Patrizio, Cardile, Davide, Murabito, Alessandra, Tripoli, Vincenzo, Verderame, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905256/
https://www.ncbi.nlm.nih.gov/pubmed/29719487
http://dx.doi.org/10.4103/wjnm.WJNM_22_17
_version_ 1783315234343092224
author Costa, Renato Patrizio
Cardile, Davide
Murabito, Alessandra
Tripoli, Vincenzo
Verderame, Francesco
author_facet Costa, Renato Patrizio
Cardile, Davide
Murabito, Alessandra
Tripoli, Vincenzo
Verderame, Francesco
author_sort Costa, Renato Patrizio
collection PubMed
description Radium 223 dichloride (Ra223) is the only targeted alpha therapy able to extend survival in patients with bone metastases from prostate cancer. Mechanism of action and data currently available focused mainly on osteoblastic metastases from prostate cancer. In our institution, a patient with breast cancer affected by osteolytic metastases was treated with off-label use of Ra223. The evaluation of the deposit areas of Ra223 showed a perfect overlap with the regions of osteolysis previously detected by scintigraphy, indicating a possible therapeutic effect. This case report is the first document attesting Ra223 deposit in osteolytic metastases opening new opportunity of therapeutic development for this radiopharmaceutical.
format Online
Article
Text
id pubmed-5905256
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-59052562018-05-01 Ra223 in Bone Metastases with Osteolytic Activity Costa, Renato Patrizio Cardile, Davide Murabito, Alessandra Tripoli, Vincenzo Verderame, Francesco World J Nucl Med Case Report Radium 223 dichloride (Ra223) is the only targeted alpha therapy able to extend survival in patients with bone metastases from prostate cancer. Mechanism of action and data currently available focused mainly on osteoblastic metastases from prostate cancer. In our institution, a patient with breast cancer affected by osteolytic metastases was treated with off-label use of Ra223. The evaluation of the deposit areas of Ra223 showed a perfect overlap with the regions of osteolysis previously detected by scintigraphy, indicating a possible therapeutic effect. This case report is the first document attesting Ra223 deposit in osteolytic metastases opening new opportunity of therapeutic development for this radiopharmaceutical. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC5905256/ /pubmed/29719487 http://dx.doi.org/10.4103/wjnm.WJNM_22_17 Text en Copyright: © 2018 World Journal of Nuclear Medicine http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Costa, Renato Patrizio
Cardile, Davide
Murabito, Alessandra
Tripoli, Vincenzo
Verderame, Francesco
Ra223 in Bone Metastases with Osteolytic Activity
title Ra223 in Bone Metastases with Osteolytic Activity
title_full Ra223 in Bone Metastases with Osteolytic Activity
title_fullStr Ra223 in Bone Metastases with Osteolytic Activity
title_full_unstemmed Ra223 in Bone Metastases with Osteolytic Activity
title_short Ra223 in Bone Metastases with Osteolytic Activity
title_sort ra223 in bone metastases with osteolytic activity
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905256/
https://www.ncbi.nlm.nih.gov/pubmed/29719487
http://dx.doi.org/10.4103/wjnm.WJNM_22_17
work_keys_str_mv AT costarenatopatrizio ra223inbonemetastaseswithosteolyticactivity
AT cardiledavide ra223inbonemetastaseswithosteolyticactivity
AT murabitoalessandra ra223inbonemetastaseswithosteolyticactivity
AT tripolivincenzo ra223inbonemetastaseswithosteolyticactivity
AT verderamefrancesco ra223inbonemetastaseswithosteolyticactivity

Ejemplares similares